Scioderm, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.sderm.com
Clinical Trials
13
Active:7
Completed:4
Trial Phases
3 Phases
Phase 1:7
Phase 2:2
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
7 (53.8%)Phase 3
4 (30.8%)Phase 2
2 (15.4%)Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Scioderm, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT02670330
ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Phase 3
Completed
- Conditions
- Epidermolysis Bullosa
- Interventions
- Drug: Placebo (SD-101-0.0) cream
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Scioderm, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT02384460
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Phase 2
Terminated
- Conditions
- Epidermolysis Bullosa
- Interventions
- Drug: SD-101 dermal cream (6%)
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Scioderm, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02090283
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
Phase 2
Completed
- Conditions
- Epidermolysis Bullosa
- Interventions
- Drug: SD-101 Dermal Cream (6%)Drug: SD-101 dermal cream (3%)Drug: Vehicle (SD-101 0%)
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Scioderm, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02014376
News
No news found